

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 01017/35966A	Serial No. 09/724,126
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant Han et al.			
		Filing Date 11-28-00	Group 1652		

MAR 22 2002
PATENT & TRADEMARK OFFICE
U.S. PATENT AND TRADEMARK OFFICE
RECEIVED
MAY 26 2002
RECEIVED
MAY 26 2002

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
ES	A1	5,861,312	1/19/99	Varshavsky et al.	435	325	12/2/97

FOREIGN PATENT DOCUMENTS							Translation	
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Yes	No
ES	B1	WO 98/23283	06/04/98	PCT	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
ES	C1	Ciechanover, "The ubiquitin-proteasome pathway: on protein death and cell life", <i>EMBO J</i> 17:7151-7160, 1998.
ES	C2	Reiss and Hershko, "Affinity purification of ubiquitin-protein ligase on immobilized protein substrates", <i>J Biol Chem</i> 265:3685-3690, 1990.
ES	C3	Kwon et al., "The mouse and human genes encoding the recognition component of the N-end rule pathway", <i>Proc Natl Acad Sci, USA</i> 95:7898-7903, 1998.
ES	C4	Bartel et al., "The recognition component of the N-end rule pathway" <i>EMBO J</i> 9:3179-3189, 1990.

EXAMINER	<i>E. Shabotyantsky</i>	DATE CONSIDERED	<i>4/21/02</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
01017/35966ASerial No.
09/724,126Applicant
Han et al.Filing Date
11-28-00Group
1652

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED
TECH CENTER MAR 26 2002
MAR 22 2002
U.S. PATENT & TRADEMARK OFFICE
C5

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages etc.)

C5	Wilson <i>et al.</i> , "2.2 Mb of contiguous nucleotide sequence from chromosome III of <i>C. elegans</i> ", <i>Nature</i> 368:32-38, 1994.
C6	Mitch and Goldberg, "Mechanisms of muscle wasting: the role of ubiquitin-proteasome pathway", <i>New England J Med</i> 335:1897-1905, 1996.
C7	Lecker <i>et al.</i> , "Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states", <i>J Nutr</i> 129:227S-237S, 1999.
C8	Solomon <i>et al.</i> , "Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway", <i>Proc Natl Acad Sci USA</i> 95:12602-12607, 1998.
C9	Baracos <i>et al.</i> , "Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachetic rats bearing a hepatoma", <i>Am J Physiol</i> 268 (<i>Endocrinol Metab</i>):E996-1006, 1995.
C10	Matsumoto <i>et al.</i> , "Tumor inoculation site-dependent induction of cachexia in mice bearing colon 26 carcinoma", <i>Brit J Cancer</i> 79:764-769, 1999.
C11	Tanaka <i>et al.</i> , "Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice", <i>Cancer Res</i> 50: 2290-2295, 1990.
C12	Database GenBank. National Library of Medicine, (Bethesda, Maryland, US), Accession No. U88308, The <i>C. elegans</i> Sequencing Consortium, "Genome sequence of the nematode <i>C. elegans</i> : a platform for investigating biology: the <i>C. elegans</i> sequencing consortium", <i>Science</i> 282:2012-2018, 1998.
C13	Database GenBank. National Library of Medicine, (Bethesda, Maryland, US), Accession No. AF061555, Kwon <i>et al.</i> , "The mouse and human genes encoding the recognition component of the N-end rule pathway", <i>Proc Natl Acad Sci, USA</i> 95:7898-7903, 1998.
C14	Database GenBank. National Library of Medicine, (Bethesda, Maryland, US), Accession No. AI187306, Strausberg, qf28h08.x1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:1751391 3', mRNA sequence; National Cancer Institute, Cancer Genome Anatomy Project, 1997.

EXAMINER

E. Slobodyanchuk

DATE CONSIDERED

11/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 01017/35966A	Serial No. 09/724,126
INFORMATION DISCLOSURE STATEMENT		Applicant Han et al.	TECH CENT MAR 2001
(Use several sheets if necessary)		Filing Date 11-28-00	

EXAMINER	<i>E. Slobodkyaesky</i>	DATE CONSIDERED	<i>11/21/02</i>
----------	-------------------------	-----------------	-----------------